pyrroles has been researched along with bm 212 in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Biava, M; Deidda, D; Fioravanti, R; Lampis, G; Pompei, R; Porretta, GC; Zanetti, S | 1 |
| Buzas, A; Duchêne, P; Houin, G; Ladure, P; Laneury, JP; Merour, JY; Ollivier, R; Tran, G | 1 |
| Biava, M; Deidda, D; Fioravanti, R; Maullu, C; Pompei, R; Porretta, GC | 1 |
| Biava, M | 1 |
| Biava, M; Cesare Porretta, G; Deidda, D; Manetti, F; Pompei, R; Tafi, A | 1 |
| Biava, M; Deidda, D; Manetti, F; Pompei, R; Porretta, GC; Tafi, A | 1 |
| Biava, M; Deidda, D; Manetti, F; Poce, G; Pompei, R; Porretta, GC; Tafi, A | 1 |
| Biava, M; Botta, M; Deidda, D; Manetti, F; Molicotti, P; Poce, G; Pompei, R; Porretta, GC; Supino, S | 1 |
| Biava, M; Manetti, F; Porretta, GC | 1 |
| Biava, M; Botta, M; De Logu, A; De Rossi, E; Manetti, F; Meleddu, R; Poce, G; Porretta, GC; Saddi, M | 1 |
| Alfonso, S; Battilocchio, C; Biava, M; Botta, M; Buroni, S; Canseco, JO; De Logu, A; De Rossi, E; Ioerger, TR; Javid, B; La Rosa, V; Manetti, F; Pasca, MR; Poce, G; Porretta, GC; Raju, RM; Rubin, EJ; Sacchettini, JC; Sorrentino, F | 1 |
| Agus, E; Alfonso, S; Ballell, L; Bates, RH; Biava, M; Botta, M; Cocozza, M; De Logu, A; De Rossi, E; Franzblau, SG; La Rosa, V; Manetti, F; Ortega, F; Pasca, MR; Poce, G; Porretta, GC; Rullas, J; Wae, B | 1 |
| Crans, DC; Crick, DC; Fontes, FL; Franzblau, SG; Grzegorzewicz, AE; Jackson, M; Jones, V; Lee, RE; Li, W; North, EJ; Upadhyay, A; Wang, Y | 1 |
| Bhakta, S; Brown, AK; Castagnolo, D; Dasugari, S; Evangelopoulos, D; Maitra, A; Manetti, F; McHugh, TD; Mortazavi, PN; Petricci, E; Scalacci, N; Twist, A | 1 |
| Chng, SS; Meshcheryakov, VA; Poce, G; Xu, Z | 1 |
| Dufrêne, YF; Kremer, L; Viela, F; Viljoen, A | 1 |
2 review(s) available for pyrroles and bm 212
| Article | Year |
|---|---|
BM 212 and its derivatives as a new class of antimycobacterial active agents.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Resistance, Bacterial; Methylation; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium; Mycobacterium tuberculosis; Piperazines; Pyrroles; Structure-Activity Relationship | 2002 |
New derivatives of BM212: A class of antimycobacterial compounds based on the pyrrole ring as a scaffold.
Topics: Antitubercular Agents; Models, Molecular; Piperazines; Pyrroles | 2007 |
1 trial(s) available for pyrroles and bm 212
| Article | Year |
|---|---|
Pharmacokinetics, metabolism and bioavailability of the new anti-allergic drug BM 113. Part III: Pharmacokinetics, metabolism, dose dependency and gender effect after single or repeated administration to human healthy volunteers.
Topics: Adult; Anti-Allergic Agents; Area Under Curve; Biological Availability; Biotransformation; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Piperidines; Pyrroles; Sex Characteristics | 1999 |
13 other study(ies) available for pyrroles and bm 212
| Article | Year |
|---|---|
Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple; Humans; Macrophages; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Piperazines; Pyrroles; U937 Cells | 1998 |
New pyrrole derivatives as antimycobacterial agents analogs of BM212.
Topics: Antitubercular Agents; Microbial Sensitivity Tests; Mycobacterium; Piperazines; Pyrroles | 1999 |
Importance of the thiomorpholine introduction in new pyrrole derivatives as antimycobacterial agents analogues of BM 212.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antifungal Agents; Antitubercular Agents; Antiviral Agents; Binding Sites; Chemical Phenomena; Chemistry, Physical; Indicators and Reagents; Isoniazid; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Morpholines; Mycobacterium; Piperazines; Pyrroles; Rifampin; Streptomycin; Structure-Activity Relationship | 2003 |
Antimycobacterial compounds. New pyrrole derivatives of BM212.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; In Vitro Techniques; Microbial Sensitivity Tests; Mycobacterium; Piperazines; Pyrroles | 2004 |
Antimycobacterial compounds. Optimization of the BM 212 structure, the lead compound for a new pyrrole derivative class.
Topics: Antitubercular Agents; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Piperazines; Pyrroles | 2005 |
Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Microbial Sensitivity Tests; Models, Molecular; Morpholines; Mycobacterium tuberculosis; Piperazines; Pyrroles; Quantitative Structure-Activity Relationship; Vero Cells | 2006 |
1,5-Diphenylpyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Piperazines; Pyrroles; Structure-Activity Relationship | 2008 |
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.
Topics: Animals; Antitubercular Agents; Carbon Radioisotopes; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cattle; DNA Mutational Analysis; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Genomic Library; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Mycobacterium bovis; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Mycobacterium tuberculosis; Piperazines; Pyrroles; Reserpine; Verapamil | 2012 |
Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.
Topics: Animals; Antibiotics, Antitubercular; Bacterial Proteins; Cell Line; Female; Humans; Mice; Microbial Sensitivity Tests; Microsomes; Mycobacterium tuberculosis; Piperazines; Pyrroles; Tuberculosis | 2013 |
Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
Topics: Adamantane; Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carrier Proteins; Cell Membrane; Cord Factors; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Mycobacterium smegmatis; Mycobacterium tuberculosis; Mycolic Acids; Phenylurea Compounds; Piperazines; Proton Ionophores; Pyrroles; Tuberculosis, Multidrug-Resistant; Valinomycin; Vitamin K 2 | 2014 |
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
Topics: Adamantane; Antitubercular Agents; Carrier Proteins; Cell Line; Cell Survival; Computational Biology; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium; Mycobacterium tuberculosis; Pharmaceutical Preparations; Piperazines; Pyrroles; Structure-Activity Relationship | 2016 |
MmpL3 is the flippase for mycolic acids in mycobacteria.
Topics: Bacterial Proteins; Cord Factors; Lipid Metabolism; Membrane Proteins; Mycobacterium smegmatis; Mycolic Acids; Piperazines; Pyrroles; Spheroplasts | 2017 |
Fast chemical force microscopy demonstrates that glycopeptidolipids define nanodomains of varying hydrophobicity on mycobacteria.
Topics: Bacterial Proteins; Biological Transport; Cell Membrane; Glycoconjugates; Hydrophobic and Hydrophilic Interactions; Membrane Microdomains; Membrane Transport Proteins; Microscopy, Atomic Force; Mycobacterium abscessus; Mycolic Acids; Piperazines; Pyrroles | 2020 |